Floatz logo

Mebendazole

Oligodendroblastoma

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Oligodendroblastoma cohort.

Asset / SponsorPhaseRating
EMPM
National Cancer Institute (NCI)
Phase 2B
Plerixafor
Lawrence D Recht
Phase 2B
Niraparib
University of Oklahoma
Phase 2CCC

Same molecule, other indications

Mebendazole is also rated in:

Overall SurvivalDormant
B
Indicative ·
60 / 100
View asset →
childhood brain stem gliomaDormant
B
Indicative ·
60 / 100
View asset →
anaplastic astrocytomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →